Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab Rollover Study in Sickle Cell Disease
NCT04657822Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Primary endpoint: Not Applicable. Started Jun 2021; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04657822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657822.